In PhI­II da­ta, Eli Lil­ly’s Retev­mo meets pri­ma­ry end­point of im­prov­ing pro­gres­sion-free sur­vival

Eli Lil­ly’s Retev­mo to treat ad­vanced or metasta­t­ic re­arranged dur­ing trans­fec­tion (RET)-mu­tant medullary thy­roid can­cer (MTC) showed promis­ing re­sults at im­prov­ing pro­gres­sion-free sur­vival com­pared to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER